ACRS

Over the past six months, Aclaris Therapeutics' stock (ACRS) has seen significant increases, including 14.06% in the past month, 112.96% year-to-date as of August 21, 2026, and 256.11% over the last 12 months. As of September 11, 2026, the share price was $5.32, marking a 172.82% increase from September 12, 2025, with a 52-week high of $6.60 and a low of $1.74. Key events include the Q2 2026 earnings release reporting a net loss of $21.5 million and $1.6 million in revenue, the FDA granting Fast Track Designation for modzatinib (ATI-2138), positive Phase 1a results for ATI-052 and reaffirmed timelines for other clinical trials, Canaccord Genuity initiating coverage with a 'Buy' recommendation and a consensus 'Buy' rating among analysts with a median target price of $12.21, scheduled participation in the 2026 Cantor Global Healthcare Conference, and a new risk of shareholder dilution identified after the company sold 7.3 million shares for $40.2 million to fund operations.